001540.KQ Ahn-Gook Pharmaceutical Co. Ltd

Healthcare Pharmaceuticals KOSDAQ
9,450 KRW
Close of Oct 31, 2026
6,949 13,650
Market cap
KRW 107B
P/E
5.0x
P/B
0.60x
ROE
23.4%
Dividend yield
4.66%
Fundamental score
4.3/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 001540.KQ undervalued?

Graham number
Price9,450
Graham value25,907
Discount63.5%

001540.KQ trades 63.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ahn-Gook Pharmaceutical Co. Ltd fundamental analysis

18 of 22 checks passed

ROE 2/2

High return on equity (23.4%), above 20%.

ROA 1/1

Return on assets (12.6%) is above the industry median (3.4%).

Profit Consistency 2/2

Profitable for 5 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-55.6%) is below the industry median (6.6%).

Revenue Growth 2/2

Revenue grew 14.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (28.0%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 22.0x against interest expense, well covered.

PE vs Market 1/1

PE (5.0x) is below the market median (11.3x).

PE vs Industry 1/1

PE (5.0x) is below the industry median (19.4x).

PBV 1/1

Price to book (0.6x) is below the industry median (0.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 3.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 2/2

Dividend yield (4.7%) is in the top 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 66.8%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Ahn-Gook Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ahn-Gook Pharmaceutical Co. Ltd

Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.

Full company profile